FAQs

Challenge Organizers

Why is Pfizer sponsoring this Challenge?

Based on the limited understanding of the needs surrounding patients with mBC, Pfizer, working collaboratively with the European School of Oncology (ESO) and within the scope of the Advanced Breast Cancer Third International Consensus Conference (ABC3), commissioned The Global Status of Advanced/Metastatic Breast Cancer 2005-2015 Decade Report to better understand the unique needs of patients living with mBC. With the current state of metastatic breast cancer in mind, Pfizer would like to take the next step towards advancing care for mBC patients including addressing their unique challenges.  

What is Health 2.0’s role?

Health 2.0 is the Challenge administrator who provides Challenge management expertise and expert guidance on innovation competition design. Through the duration of the Challenge, Health 2.0 maintains the Challenge website, recruits judges for the initial judging of Phase I and supports the evaluation process as well as marketing promotions. Health 2.0 also supports interested participants by answering questions throughout the submission and application process.

 

Eligibility

Who is eligible to apply to the Challenge?

Teams and individuals around the world who are 18 years old or older are eligible to apply to the Challenge.

This includes organizations, technologists, entrepreneurs, designers, developers, and innovators. Startup companies, non-profits and educational institutions are also included in our definition of an "organization."

We are committed to receiving applications from a diverse range of organizations. If you are unsure about your eligibility, please contact us at challenges@health2con.com.  You may also refer to the Terms and Conditions on the Challenge website for more details.

 

Can team members be added after Phase I or Phase II?

Team members can be added to the selected groups that move on to Phase 2 and 3.  However, please note that the total prize money awarded for the tech-enabled solution will be awarded to the team. The team can determine if this prize money should be awarded to one individual or distributed amongst team members, and if so, the ratio of the distribution can be determined by the team.

 

Can I apply as an individual?

Yes, you can absolutely apply as an individual, as long as you are 18 years old or older and not otherwise ineligible.  Please refer to the Terms and Conditions on the Challenge website for more details.

 

Can I apply as a team? Are there any restrictions as to who forms that team?

Yes, you can apply as a team, as long as the team members are 18 years old or older and not otherwise ineligible.  Please refer to the Terms and Conditions on the Challenge website for more details. Note that the total prize money awarded for the tech-enabled solution is awarded to the team.

 

I would like to apply as a team and I’m looking for team members. Are there any resources that I can use to help me form a team?

If you’re looking for team members, you can email a brief blurb about yourself (100 words max), along with your contact information, to challenges@health2con.com.  We will review and post the final blurb on the Team Formation page on the Challenge website, so that others can reach out to you.  Be sure to share more about yourself and what you’re looking for in teammates.  Remember, you are eligible to apply as a team or an individual!

 

I am already doing business with Pfizer. Can I still apply to the Challenge?

If you are already doing business with Pfizer, you can apply to the Challenge, as long as you are not otherwise ineligible. See the Challenge Terms and Conditions for more details.  Please note that employees of Pfizer, Health 2.0, each of their affiliates, and/or any other individual or entity associated with the development, judging, or administration of the Challenge as well as members of such persons' immediate families (spouses, children, siblings, parents), and persons living in the same household as such persons, whether or not related, are not eligible to participate in the Challenge.

We are committed to receiving applications from a diverse range of organizations. If you are unsure about your eligibility, please contact us at challenges@health2con.com.

 

I am an early stage startup company and my solution is already built. Am I eligible to apply to the Challenge?

You are absolutely eligible to apply to the Challenge, even if you already have a developed technology. The Challenge is open to innovators and companies at any stage of development. In particular, we feel that the mentorship component is valuable to organizations with solutions at any stage of development.

In order for us to judge your entry, we still require that you complete the Official Entry Form, and submit your proposed solution in accordance with all terms and conditions specified in the Challenge Terms and Conditions and set out on the Challenge Website (i.e., a 500 word description of the proposed solution and design methodology in PDF format; mockups/wireframes in PDF or PPT format; and a journey map in PDF or PPT format).

If you have a developed technology or more mature idea, you also may contact challenges@health2con.com to provide additional materials and/or links to more information.

Please note that any materials submitted as part of the Challenge will be considered as non-confidential disclosures; however, the entrant retains title and full ownership to their submission.

 

Ownership

Who owns the IP in this Challenge?

Each entrant retains title and full ownership and intellectual property rights to their submission. If an applicant decides to sell the rights to their tech-enabled solution, Pfizer has the Right of First Negotiation, limited to 30 days, to acquire rights in any Submission or product arising out of the Challenge. This may include a potential partnership or purchase of IP, however the nature of the agreement will be determined during negotiations post Challenge. Please refer to the Challenge Terms & Conditions for more information.

 

Do I need to patent my idea before applying to the Challenge?

Each entrant retains title and full ownership and intellectual property rights to their submission. The applicant retains the right to patent their idea if they wish and is responsible for managing that process independently.  Please note however that we are accepting ideas at any stage of development including those that have and haven’t been patented.  See the Terms and Conditions on the Challenge website for more information on entrants’ intellectual property rights.

 

Submission Materials

The Challenge calls for “technology-enabled solutions,” can you elaborate on this term? What will successful solutions look like?

Our definition of “technology-enabled solution” is broad with a wide range of different kinds of solutions (not purely limited to an application, for example). We encourage you to think outside of the box and don’t be constrained!

Successful solutions should go beyond already existing oncology-related technology. They will be user-friendly, visually engaging, intuitive, and also demonstrate the potential for scalability and sustainability. They will push the limits of personalization and remain supportive as the patient’s needs change over time. We are looking for solutions that support and empower patients living with mBC along the care continuum and  address one or more of the key patient needs below:

An intuitive, customizable, and tailored care management solution that improves care and disease management for patients living with mBC, incorporating a comprehensive approach to well-being across the care continuum

 Solutions to support mBC patients with their daily living and enrich their lives

Solutions to help patients living with mBC engage and support one another

If you’re unsure if your solution qualifies, please contact challenges@health2con.com.

 

What are the Phase 1 submission requirements?

The submission requirements include a 500-word description of your proposed solution and design methodology, mockups/wireframes and a journey map. Click here for more details.

 

What is a journey map?

A journey map shows the process of how a user interacts with the solution. It should visually demonstrate how the proposed approach addresses the issues and needs of mBC patients.

We are committed to receiving your application regardless of your background and understand that some applicants may not be familiar with a journey map. If you are looking for additional guidance about what the journey map should contain or would like an example, please contact challenges@health2con.com.

 

What is a mockup/wireframe?

The mockup/wireframe is a representation of what the solution will look like, outlining the design, interface and functionality.

We are committed to receiving your application regardless of your background and understand that some applicants may not be familiar with a mockup/wireframe. If you are looking for additional guidance about what the mockup/wireframe should contain or would like an example, please contact challenges@health2con.com.

 

Judging

Q: What does the judging process look like?

Leading submissions will be reviewed by an international Steering Committee made up of oncology healthcare providers, an mBC patient and tech innovation experts. This Steering Committee will help to determine the 5 semi-finalists in Phase 1, the 3 finalists in Phase 2 and the winner & runner up in Phase 3. Please visit the Steering Committee section of the Challenge website for more information.

 

Q: When will the Phase 1 semi-finalists be selected? Are Phases 2 and 3 open to the public? 

Phase 1 semi-finalists will be selected in March 2017. Phases 2 and 3 are not open to the public. The 5 semi-finalists will advance to Phase 2, and 3 finalists out of that group will advance to Phase 3, based on the results of the mid-Challenge pitch session.

 

Mentorship

Q: Who are the mentors in Phase 2 who help with the development of solutions?

In Phase 2, mentors will provide guidance and expertise in four areas including, technical development, design, mBC patient perspective and pitch/presentation skills. The same mentors will consult with each team, virtually or otherwise, and the mentors will remain involved for the duration of Phase 2.

The technical mentor will consult with the semi-finalists to guide the development of their solutions. The design expert will provide guidance from a design strategy, user experience and human-centered design perspective. The mBC patient representative will provide guidance from the patient perspective. Lastly, a pitch training mentor will work with the finalists to prepare their presentation for the live pitch event.

 

Metastatic Breast Cancer

Q: Will mBC patients be involved in the Challenge?

A mBC patient will be involved in the judging process as part of the Steering Committee. This person will provide insight into which tech-enabled solutions are most useful and relevant to mBC patients. An mBC patient representative will also serve as a mentor in Phase 2, providing a key patient perspective and helping to guide the development of the solutions.

 

Q: How is metastatic breast cancer different from early breast cancer?

mBC is defined as the spread of cancer beyond the breast to other organs such as lung, bones and brain. Unlike early breast cancer, there is no cure for mBC and the majority of deaths from breast cancer are as a result of metastatic disease.3 Differently from early stages, metastatic disease has more limited treatment options. Patients living with mBC often experience a decreased sense of autonomy as their disease may limit them from maintaining their roles as parents, spouses, and professionals. 5-year survival rates for mBC remain poor at approximately 25%; in contrast eBC 5-year survival rates are high at approximately 98%.1 Patients with mBC often feel isolated and misunderstood as the minority in the larger breast cancer community, as eBC patients are often associated with survivorship. As a result, mBC is experienced by patients differently from early-stage breast cancer (eBC) or other cancers, which greatly affects the way patients with mBC think and feel.8,14 Furthermore, whilst median survival for mBC is an estimated 2-3 years, this can vary greatly among patients dependent on mBC subtype and other patient characteristics. Some patients can live with their disease for several years longer.1,10,11 This indefinite prognosis can leave patients and their families experiencing high levels of uncertainty and significant emotional burden.8

 

Q: How is metastatic breast cancer different from other metastatic cancers?

Unlike some metastatic cancers, mBC largely affects women (99%)12, often who are mothers, wives, grandmothers or caring for a family. Additionally, the majority of patients with mBC are diagnosed following an earlier diagnosis of breast cancer that has developed into metastatic disease (90%-95%),4 which may differ from many other metastatic cancers where patients are initially diagnosed with advanced stage disease. These patients may have been told they were cured of breast cancer and therefore suffer from high levels of emotional and psychological distress. Median overall survival for mBC is between 2-3 years and has not changed significantly over the past 10 years, although some patients can live for a longer period of time, which may differ from some other metastatic diseases.1,10,11